Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Prospective Exploratory Study of Mirogabalin for Diabetic Peripheral Neuropathic Pain
jRCTs031240623Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mirogabalin in diabetic polyneuropathy (DPN) and type 2 diabetes mellitus (T2DM), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in pain NRS at 12 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
mirogabalin
03
Conditions
diabetic polyneuropathy (DPN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031240623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240623.